skip to content
Variability in the pharmacokinetics of mycophenolic acid Implications for therapeutic drug monitoring Preview this item
ClosePreview this item
Checking...

Variability in the pharmacokinetics of mycophenolic acid Implications for therapeutic drug monitoring

Author: B C M de Winter
Publisher: [S.l.] : [The Author] ; Rotterdam : Erasmus University [Host], 2010
Dissertation: Thesis Erasmus University Rotterdam.
Edition/Format:   Thesis/dissertation : Document : Thesis/dissertation : eBook   Computer File : English
Summary:
Mycophenolate mofetil (MMF) is an immunosuppressive drug used to prevent rejection following solid organ transplantation. MMF was introduced in 1995 with a recommended fixed-dose regimen of 1 g twice daily. Nowadays, dose individualization using therapeutic drug monitoring (TDM) of the area under the concentration-time curve from 0 to 12 hours postdose (AUC0-12) of the active compound, mycophenolic acid (MPA), is  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Find a copy online

Links to this item

Find a copy in the library

We were unable to get information about libraries that hold this item.

Details

Genre/Form: Proefschriften (vorm)
Additional Physical Format: Variability in the pharmacokinetics of mycophenolic acid Implications for therapeutic drug monitoring
(NL-LeOCL)324496605
Material Type: Document, Thesis/dissertation, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: B C M de Winter
ISBN: 9789085599388 9085599385
OCLC Number: 565478587
Notes: ook verschenen in gedrukte versie.
Description: 1 online resource.
Responsibility: Brenda Cornelia Maria de Winter.

Abstract:

Mycophenolate mofetil (MMF) is an immunosuppressive drug used to prevent rejection following solid organ transplantation. MMF was introduced in 1995 with a recommended fixed-dose regimen of 1 g twice daily. Nowadays, dose individualization using therapeutic drug monitoring (TDM) of the area under the concentration-time curve from 0 to 12 hours postdose (AUC0-12) of the active compound, mycophenolic acid (MPA), is advocated to optimize the treatment. The recommended target range for the MPA AUC0-12 in renal transplant recipients is 30-60 mg*h/L. A practical and suitable manner of determining the MPA AUC0-12 are abbreviated AUC measurements, in which the AUC0-12 is estimated by a limited sampling strategy. In renal transplant recipients, it has been shown that limited sampling strategies estimate MPA AUC0-12 with sufficient accuracy and precision. The aim of this thesis was to further explain the differences in the pharmacokinetics of MMF seen between renal transplant recipients, investigate the validity of these results in other populations, or when different formulations are used, and to describe the effects of these results on individualization of the MMF treatment. In Chapter 1 of this thesis, an overview of the pharmacokinetics of MPA in renal transplant recipients and the added value of TDM are discussed. MPA is a highly protein bounded drug, which binds reversibly to albumin. The free fraction is thought to be responsible for the immunosuppressive effect of MPA. Cyclosporine comedication, low plasma albumin level, and impaired renal function are associated with a decrease in total MPA AUC, but the unbound concentration is hardly affected. The effect of these covariates on total and unbound MPA concentrations is clarified in Chapter 2.1. The effect of MMF dose on the pharmacokinetics of MPA is evaluated in Chapter 2.2. In Chapter 2.3 the differences in the pharmacokinetics of MPA between adult and pediatric renal transplant recipients are examined. Besides solid organ transplantation, MMF is increasingly used to prevent graft-versus-host disease following hematopoietic stem cell transplantation and for treatment of autoimmune diseases. TDM may be a valuable tool to optimize MMF therapy in these patients as well. The differences in the pharmacokinetics of ... [ingekort].

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/565478587> # Variability in the pharmacokinetics of mycophenolic acid Implications for therapeutic drug monitoring
    a schema:MediaObject, pto:Web_document, schema:CreativeWork, schema:Book, bgn:Thesis ;
   bgn:inSupportOf "Thesis Erasmus University Rotterdam." ;
   library:oclcnum "565478587" ;
   library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/377942757#Place/s_l> ; # S.l.
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/ne> ;
   library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/377942757#Place/rotterdam> ; # Rotterdam
   schema:creator <http://viaf.org/viaf/287571022> ; # Brenda Cornelia Maria Winter
   schema:datePublished "2010" ;
   schema:description "Mycophenolate mofetil (MMF) is an immunosuppressive drug used to prevent rejection following solid organ transplantation. MMF was introduced in 1995 with a recommended fixed-dose regimen of 1 g twice daily. Nowadays, dose individualization using therapeutic drug monitoring (TDM) of the area under the concentration-time curve from 0 to 12 hours postdose (AUC0-12) of the active compound, mycophenolic acid (MPA), is advocated to optimize the treatment. The recommended target range for the MPA AUC0-12 in renal transplant recipients is 30-60 mg*h/L. A practical and suitable manner of determining the MPA AUC0-12 are abbreviated AUC measurements, in which the AUC0-12 is estimated by a limited sampling strategy. In renal transplant recipients, it has been shown that limited sampling strategies estimate MPA AUC0-12 with sufficient accuracy and precision. The aim of this thesis was to further explain the differences in the pharmacokinetics of MMF seen between renal transplant recipients, investigate the validity of these results in other populations, or when different formulations are used, and to describe the effects of these results on individualization of the MMF treatment. In Chapter 1 of this thesis, an overview of the pharmacokinetics of MPA in renal transplant recipients and the added value of TDM are discussed. MPA is a highly protein bounded drug, which binds reversibly to albumin. The free fraction is thought to be responsible for the immunosuppressive effect of MPA. Cyclosporine comedication, low plasma albumin level, and impaired renal function are associated with a decrease in total MPA AUC, but the unbound concentration is hardly affected. The effect of these covariates on total and unbound MPA concentrations is clarified in Chapter 2.1. The effect of MMF dose on the pharmacokinetics of MPA is evaluated in Chapter 2.2. In Chapter 2.3 the differences in the pharmacokinetics of MPA between adult and pediatric renal transplant recipients are examined. Besides solid organ transplantation, MMF is increasingly used to prevent graft-versus-host disease following hematopoietic stem cell transplantation and for treatment of autoimmune diseases. TDM may be a valuable tool to optimize MMF therapy in these patients as well. The differences in the pharmacokinetics of ... [ingekort]." ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/377942757> ;
   schema:genre "Proefschriften (vorm)" ;
   schema:inLanguage "en" ;
   schema:isSimilarTo <http://worldcat.org/entity/work/data/377942757#CreativeWork/variability_in_the_pharmacokinetics_of_mycophenolic_acid_implications_for_therapeutic_drug_monitoring> ;
   schema:name "Variability in the pharmacokinetics of mycophenolic acid Implications for therapeutic drug monitoring" ;
   schema:productID "565478587" ;
   schema:publication <http://www.worldcat.org/title/-/oclc/565478587#PublicationEvent/s_l_the_author_rotterdam_erasmus_university_host_2010_rotterdam_optima_grafische_communicatie> ;
   schema:publisher <http://experiment.worldcat.org/entity/work/data/377942757#Agent/the_author> ; # [The Author]
   schema:publisher <http://experiment.worldcat.org/entity/work/data/377942757#Agent/erasmus_university_host> ; # Erasmus University [Host]
   schema:url <http://hdl.handle.net/1765/18480> ;
   schema:workExample <http://worldcat.org/isbn/9789085599388> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/565478587> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/377942757#Agent/erasmus_university_host> # Erasmus University [Host]
    a bgn:Agent ;
   schema:name "Erasmus University [Host]" ;
    .

<http://viaf.org/viaf/287571022> # Brenda Cornelia Maria Winter
    a schema:Person ;
   schema:birthDate "1982" ;
   schema:familyName "Winter" ;
   schema:givenName "Brenda Cornelia Maria" ;
   schema:givenName "B.C.M. de" ;
   schema:name "Brenda Cornelia Maria Winter" ;
    .

<http://worldcat.org/entity/work/data/377942757#CreativeWork/variability_in_the_pharmacokinetics_of_mycophenolic_acid_implications_for_therapeutic_drug_monitoring>
    a schema:CreativeWork ;
   rdfs:label "Variability in the pharmacokinetics of mycophenolic acid Implications for therapeutic drug monitoring" ;
   schema:isSimilarTo <http://www.worldcat.org/oclc/565478587> ; # Variability in the pharmacokinetics of mycophenolic acid Implications for therapeutic drug monitoring
    .

<http://worldcat.org/isbn/9789085599388>
    a schema:ProductModel ;
   schema:isbn "9085599385" ;
   schema:isbn "9789085599388" ;
    .

<http://www.worldcat.org/title/-/oclc/565478587>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
   schema:about <http://www.worldcat.org/oclc/565478587> ; # Variability in the pharmacokinetics of mycophenolic acid Implications for therapeutic drug monitoring
   schema:dateModified "2018-03-09" ;
   void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.